# US 2018/0022824 A1 · Complement inhibition for improved nerve regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022824 A1
- Document ID: US20180022824A1
- Status: Published application
- Kind: A1
- Application number: 15/673,167
- Filed: 2017-08-09
- Published: 2018-01-25
- Earliest claimed: 2006-10-10
- Assignees: Regenesance B.V.
- Applicants: Regenesance B.V.
- Inventors: Frank BAAS; Valeria RAMAGLIA
- Web page: https://patentgrep.com/patent/US20180022824A1

## CPC

- C07K 16/40: against enzymes
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/727: Heparin; Heparan
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method of inhibiting the formation of membrane attack complex (MAC) in a subject diagnosed with a neurodegenerative disorder or physical injury of a nerve, comprising administering to the subject a therapeutically effective amount of an inhibitor of a mammalian complement system, wherein the inhibitor is an antisense oligonucleotide that binds to the mRNA sequence of human C5 or C6 of the complement system.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the physical injury is of the peripheral or central nervous system.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the neurodegenerative disorder is of the peripheral or central nervous system.

### Claim 18 (depends on 15)

The method according to claim 15, wherein the neurodegenerative disorder is Amyotrophic Lateral Sclerosis (ALS).

### Claim 19 (depends on 15)

The method of claim 15, wherein the antisense oligonucleotide is administered by an intradermal, intramuscular, intraperitoneal, intravenous, or subcutaneous route.

### Claim 20 (depends on 15)

The method according to claim 15, wherein the neurodegenerative disorder is Multiple Sclerosis (MS).

### Claim 21

(canceled)

### Claim 22

A method of promoting functional recovery of damaged or degenerating nerves in a subject by inhibiting the formation of membrane attack complex, comprising administering to the subject a therapeutically effective amount of an inhibitor of a mammalian complement system, wherein the inhibitor is an antisense oligonucleotide that binds to the mRNA sequence of human C5 or C6 of the complement system.

### Claim 23 (depends on 15, 22)

The method of claim 15 or 22, wherein the antisense oligonucleotide is administered by an intradermal, intramuscular, intraperitoneal, intravenous, or subcutaneous route.

### Claim 24 (depends on 15, 22)

The method of claim 15 or 22 wherein the damaged or degenerating nerves are of the PNS or CNS.

### Claim 25 (depends on 15, 22)

The method of claim 15 or 22, wherein the antisense oligonucleotide comprises one or more locked nucleic acids (LNA).

### Claim 26

(canceled)

### Claim 27 (depends on 15, 22)

The method of claim 15 or 22, wherein the antisense oligonucleotide comprises one or more peptide nucleic acids (PNA) or ethylene-bridged nucleotides (ENA).

### Claim 28

A method of inhibiting the formation of membrane attack complex (MAC) in a subject diagnosed with a neurodegenerative disorder or physical injury of a nerve, comprising administering to the subject a therapeutically effective amount of an inhibitor of a mammalian complement system, wherein the inhibitor is a complement receptor.
